In vivo reversal of amyloid-β lesions in rat brain

EM Sigurdsson, B Permanne, C Soto… - … of Neuropathology & …, 2000 - academic.oup.com
EM Sigurdsson, B Permanne, C Soto, T Wisniewski, B Frangione
Journal of Neuropathology & Experimental Neurology, 2000academic.oup.com
Cerebral amyloid-β (Aβ) deposition is central to the neuropathological definition of
Alzheimer disease (AD) with Aβ related toxicity being linked to its β-sheet conformation
and/or aggregation. We show that a β-sheet breaker peptide (iAβ5) dose-dependently and
reproducibly induced in vivo disassembly of fibrillar amyloid deposits, with control peptides
having no effect. The iAβ5-induced disassembly prevented and/or reversed neuronal
shrinkage caused by Aβ and reduced the extent of interleukin-1β positive microglia-like cells …
Abstract
Cerebral amyloid-β (Aβ) deposition is central to the neuropathological definition of Alzheimer disease (AD) with Aβ related toxicity being linked to its β-sheet conformation and/or aggregation. We show that a β-sheet breaker peptide (iAβ5) dose-dependently and reproducibly induced in vivo disassembly of fibrillar amyloid deposits, with control peptides having no effect. The iAβ5-induced disassembly prevented and/or reversed neuronal shrinkage caused by Aβ and reduced the extent of interleukin-1β positive microglia-like cells that surround the Aβ deposits. These findings suggest that β-sheet breakers, such as iAβ5 or similar peptidomimetic compounds, may be useful for reducing the size and/or number of cerebral amyloid plaques in AD, and subsequently diminishing Aβ-related histopathology.
Oxford University Press